TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01347645
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
Study: NCT02112838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily by mouth, over the course of 24 weeks
Study: NCT00201721
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
Study: NCT01414374
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
Study: NCT01414374
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
Study: NCT01101906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally
Study: NCT03556033
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks treatment with placebo capsules on top of insulin treatment
Study: NCT00512525
Drug: Ghrelin and saline (as placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00883051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01284868
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03998982
Drug: Glycyrrhetinic Acid
Normalized name: Glycyrrhetinic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound glycyrrhizin tablets 75 mg three times per day, 1 month
Study: NCT00269893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo soulution either bolus or infusion.
Study: NCT03254485
Drug: IW-1973
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03254485
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT00832182
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
Study: NCT01115452
Drug: 5% Potassium nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% potassium nitrate solution
Study: NCT01115452
Drug: 2.5% Potassium nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% potassium nitrate solution
Study: NCT02941562
Drug: FOLFOX4 chemotherapy,preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Study: NCT02941562
Drug: Concurrent chemotherapy of neo-adjuvant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 825mg/m2 twice daily 5 days/week
Study: NCT00004817
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02941562
Drug: FOLFOX4 chemotherapy,post-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Study: NCT04820907
Drug: HCP1904-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04820907
Drug: RLD2001-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT02452047
Drug: Placebo to CMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to CMS IV infusion once every 12 hours
Study: NCT00017641
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02242461
Drug: Rhodiola placebo capsules
Normalized name: RHODIOLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn starch
Study: NCT02242461
Drug: Rhodiola Crenulata
Normalized name: RHODIOLA CRENULATA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola Crenulata
Study: NCT00153062
Drug: Aggrenox placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00153062
Drug: Micardis placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02112032
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
Study: NCT01550445
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
Study: NCT04290936
Drug: Vemlidy® (Tenofovir Alafenamide; TAF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
Study: NCT04290936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
Study: NCT01715831
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
Study: NCT00187408
Drug: Low Molecular Weight Heparin (dalteparin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01198405
Drug: Guideline-driven standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
Study: NCT01786473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01748370
Drug: Placebo hypogonadal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01748370
Drug: Placebo eugonadal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02995993
Drug: Moss-aGal (recombinant human alpha-galactosidase A produced in moss)
Normalized name: Streptococcus agalactiae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
Study: NCT02940405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo given as a tablet one hour before staring the root canal treatment
Study: NCT03341767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-wax in gelatin capsule
Study: NCT01346865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1tablet bid
Study: NCT04200885
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
Study: NCT01429090
Drug: Vagantin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
Study: NCT01058447
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, 250 mg, single dose
Study: NCT01459926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT04184401
Drug: Ascites replacement with albumin and hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution
Study: NCT04184401
Drug: Ascites replacement with hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution only strategy for ascites replacement~- 70% of ascites: replacement with Hartmann's solution
Study: NCT00103454
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02018133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2 capsule daily
Study: NCT01774981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02669875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
Study: NCT02360046
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
Study: NCT00596427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets: 3 tablets twice per day
Study: NCT02360046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
Study: NCT00599911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral, once daily for 6 weeks
Study: NCT04366245
Drug: Standard of care for SARS-CoV-2 infection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for SARS-CoV-2 infection
Study: NCT03588273
Drug: Amoxil 500 MG Oral Capsule
Normalized name: Amoxil 500 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01210638
Drug: Oxymorphone
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet
Study: NCT01746719
Drug: Etodolac Capsules USP 300 mg
Normalized name: etodolac Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg capsule once a day
Study: NCT01746719
Drug: Etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablet once a day
Study: NCT03194776
Drug: LLG783
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Study: NCT03194776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Study: NCT05306990
Drug: Rosuvastatin 20 Mg Oral Tablet
Normalized name: rosuvastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients followed up for 3 months
Study: NCT00716612
Drug: Coenzyme Q 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO Coenzyme Q 10 120 mg QD
Study: NCT00716612
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: po Placebo QD
Study: NCT01206465
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00057811
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, IT, or orally
Study: NCT00057811
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00057811
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT
Study: NCT00057811
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00057811
Drug: hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT02117336
Drug: P1446A-05
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death.
Study: NCT01659138
Drug: SAR339658
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT02191826
Drug: SOM0226
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05567536
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
Study: NCT01248780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
Study: NCT01248780
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
Study: NCT02460510
Drug: 3% hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00333138
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 capsule was taken orally once a day
Study: NCT00333138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.25 mg capsule was given once daily
Study: NCT02320721
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Study: NCT00122057
Drug: antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00798915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1% human albumin in normal saline
Study: NCT01435330
Drug: BVS857
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04636697
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Study: NCT01435330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03693404
Drug: Marcaine, Duramorph , ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
Study: NCT03693404
Drug: General Anesthetics
Normalized name: GENERAL ANESTHETICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will only receive standard of care general anesthesia
Study: NCT00876486
Drug: Genexol-PM®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
Study: NCT02032277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Veliparib
Study: NCT00876486
Drug: Genexol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
Study: NCT03927443
Drug: SDP-133
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop
Study: NCT00626288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cpr, t.i.d. 12 weeks
Study: NCT03439137
Drug: MT-6548-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02704767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733836
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00914121
Drug: SKI-606
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00914121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03676036
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173782
Drug: Berodual® Respimat ® high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173782
Drug: Berodual® Respimat ® low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173782
Drug: Berodual® MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01663623
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine
Study: NCT00848016
Drug: R-(-)-gossypol acetic acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT04456686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given IV.
Study: NCT00551265
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02817230
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01225549
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for nebulisation once daily 7 days
Study: NCT01033396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: NCT01225549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation once daily 7 days
Study: NCT00743210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 grams once per day for 3 weeks.
Study: NCT02659644
Drug: Oral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
Study: NCT04337632
Drug: Doxorubicin Hydrochloride Liposome Injection+carboplatin
Normalized name: doxorubicin hydrochloride liposome Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
Study: NCT03186326
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours
Study: NCT03651804
Drug: Non-steroidal anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
Study: NCT03651804
Drug: Bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
Study: NCT03651804
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
Study: NCT03651804
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
Study: NCT00473083
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Study: NCT02029846
Drug: Incretin-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: incretin-based drugs
Study: NCT00473083
Drug: Clindamycin 2% in hydrocortisone 1% lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.